A
ANI Pharmaceuticals D
D
ANIP
94.160
USD
-0.69
(-0.73%)
مغلق
حجم التداول
10,265
الربح لكل سهم
7
العائد الربحي
-
P/E
-136
حجم السوق
2,098,983,836
الأخبار المقالات
العنوان: ANI Pharmaceuticals
القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.